What's Happening?
Zoetis Inc., a leading animal health company, has received marketing authorization from the European Commission for its Poulvac Procerta HVT-ND vaccine. This recombinant vector vaccine is designed to protect chickens against Newcastle disease and Marek's
disease with a single dose. The vaccine can be administered in ovo or by subcutaneous injection at hatch. Newcastle disease is a significant concern in the poultry industry, causing mortality and production losses, as evidenced by recent outbreaks in Germany, Spain, and Poland. The vaccine uses the herpesvirus of turkey (HVT) as a vector, which has been a reliable method in poultry vaccination for two decades. This approval not only provides European poultry producers with a new tool to combat these diseases but also opens export opportunities to Southeast Asian countries where the vaccine is already approved.
Why It's Important?
The approval of Poulvac Procerta HVT-ND is significant for the poultry industry, particularly in Europe, where recent outbreaks of Newcastle disease have highlighted the need for effective vaccination strategies. By providing a single-dose solution that protects against both Newcastle and Marek's diseases, Zoetis is addressing a critical need for poultry health management. This development is expected to enhance poultry production efficiency and reduce economic losses associated with these diseases. Additionally, the approval facilitates international trade, benefiting poultry producers in regions with high demand for effective disease management solutions. The vaccine's approval also underscores Zoetis's commitment to innovation in animal health, potentially setting new standards for poultry disease prevention.
What's Next?
Following the European Commission's approval, Zoetis plans to collaborate with veterinarians and poultry producers to integrate Poulvac Procerta HVT-ND into existing flock health programs. The company aims to leverage its established HVT vector platform to support poultry producers in Europe and Southeast Asia. As the vaccine becomes more widely used, it may lead to a reduction in the incidence of Newcastle and Marek's diseases, improving overall poultry health and productivity. Zoetis will likely continue to monitor the vaccine's performance and gather data to support its efficacy and safety, potentially paving the way for further approvals in other regions.
